Xilio Therapeutics has reported promising results from its Phase 2 clinical trial involving vilastobart, a novel immunotherapy targeting metastatic microsatellite stable colorectal cancer (MSS CRC).

RTA is committed to enhancing Dubai’s global leadership in autonomous mobility by trialling various types of autonomous vehicles, air taxis, and marine transport, with the ultimate goal of ...

The trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics. It also showed that KER-065 was generally well-tolerated, with no serious adverse events or dose ...

Actinium outlined its 2025 business objectives for its revitalized and expanding clinical pipeline as follows: Pipeline Expansion into Prostate Cancer with ATNM-400, a first-in-class, non-PSMA ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio, Senior Trial Design Lead, One2Treat, discusses the company's main goals for attending the SCOPE Summit, ...

CONSHOHOCKEN, Pa. and KING OF PRUSSIA, Pa., Jan. 13, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company specializing in randomization and trial supply management, consent, and ...

CONSHOHOCKEN, Pa. and KING OF PRUSSIA, Pa., Jan. 13, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company specializing in randomization and trial supply management, consent, and ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 ...